AXAM Therapeutics Revenue

Biotechnology Research • Mainz, Rhineland-Palatinate, Germany • 1-10 Employees

AXAM Therapeutics revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$273,776
Total funding	No funding

Key Contact at AXAM Therapeutics

Khelifa Arab

Co-Founder

Company overview

Headquarters	Mainz, Rhineland-Palatinate, Germany
NAICS	541714
Founded	2022
Employees	1-10

About AXAM Therapeutics

AXAM Therapeutics explores the epigenetic paradigm to disrupt the drug discovery concepts in human chronic diseases. Our vision took the source from the pioneering work of the founder Khelifa Arab at the German Cancer Research Center (DKFZ) and Institute of Molecular Biology Mainz (IMB) on the epigenetic regulation of tumor and metastasis suppressor genes by regulatory RNAs and R-loops structures. AXAM developed novel tools to define tumor epigenome weakness that enable us to select target proteins suitable for innovative drug development, i.e, small molecules and/or biologics. AXAM spearheaded a research therapeutic program in oncology and gathered two experienced cancer epigenetics and business strategy members in a creative team, aiming to reinforce the team with digital chemistry and drug developer experts. AXAM Therapeutics aims to fight against lethal chronic diseases and reinvest profits into sustainable epigenetic research.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

AXAM Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

AXAM Therapeutics has never raised funding before.

Frequently asked questions

AXAM Therapeutics is located in Mainz, Rhineland-Palatinate, DE.

AXAM Therapeutics generates an estimated annual revenue of $85,555. This revenue figure reflects the company's market position and business performance in its industry.

AXAM Therapeutics has an estimated valuation of $273,776. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

AXAM Therapeutics was founded in 2022, making it 4 years old. The company has established itself as a significant player in its industry over this time.

AXAM Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at AXAM Therapeutics

Khelifa Arab

Co-Founder

4.8

40,000 users